Download MendeleyDiscovery of Potent and Selective Allosteric Inhibitors of Protein Arginine Methyltransferase 3 (PRMT3).
Kaniskan, H.U., Eram, M.S., Zhao, K., Szewczyk, M.M., Yang, X., Schmidt, K., Luo, X., Xiao, S., Dai, M., He, F., Zang, I., Lin, Y., Li, F., Dobrovetsky, E., Smil, D., Min, S.J., Lin-Jones, J., Schapira, M., Atadja, P., Li, E., Barsyte-Lovejoy, D., Arrowsmith, C.H., Brown, P.J., Liu, F., Yu, Z., Vedadi, M., Jin, J.(2018) J Med Chem 61: 1204-1217
- PubMed: 29244490 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acs.jmedchem.7b01674
- Primary Citation Related Structures:
4QQN - PubMed Abstract:
PRMT3 catalyzes the asymmetric dimethylation of arginine residues of various proteins. It is crucial for maturation of ribosomes and has been implicated in several diseases. We recently disclosed a highly potent, selective, and cell-active allosteric inhibitor of PRMT3, compound 4. Here, we report comprehensive structure-activity relationship studies that target the allosteric binding site of PRMT3. We conducted design, synthesis, and evaluation of novel compounds in biochemical, selectivity, and cellular assays that culminated in the discovery of 4 and other highly potent (IC 50 values: ∼10-36 nM), selective, and cell-active allosteric inhibitors of PRMT3 (compounds 29, 30, 36, and 37). In addition, we generated compounds that are very close analogs of these potent inhibitors but displayed drastically reduced potency as negative controls (compounds 49-51). These inhibitors and negative controls are valuable chemical tools for the biomedical community to further investigate biological functions and disease associations of PRMT3.
- Center for Chemical Biology and Drug Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai , New York, New York 10029, United States.
Organizational Affiliation:
